CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 80 enrolled
Drug / intervention
Vildagliptin 50 mg Oral Tablet +2 moredrug
Likely dose
Vildagliptin 50 mg Oral Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03693560
NCT03693560Phase 4Completed
CompareCT.gov

The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases

Damanhour University·interventional·Posted Oct 3, 2018·Updated Jun 13, 2023

In Brief

A Phase 4 clinical trial evaluating Vildagliptin 50 mg Oral Tablet, Metformin 1000 mg Oral Tablet, and 1 other intervention for Coronary Artery Disease and Diabetes Mellitus, Type 2. Completed, enrolled 80 participants across 1 site.

Detailed Summary

The aim of this study is to evaluate the effect of adding Vildagliptin versus Glimepiride to Metformin on markers of inflammation, thrombosis, and atherosclerosis in diabetic patients with symptomatic Coronary artery diseases. The pre-specified established biological markers of inflammation, thrombosis, and atherosclerosis will include: Interleukin 1 beta (IL-1 beta)), hs-CRP, Atherogenic index and coronary risk index, Lipid profile. and adiponectin levels..

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Diabetes Mellitus, Type 2
CountriesEgypt
CollaboratorsTanta University

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedOct 3, 2018
Enrollment StartOct 8, 2018
Primary CompletionSep 10, 2019
Study CompletionOct 10, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.7 years ago

Interventions

Vildagliptin 50 mg Oral Tabletdrug

Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.

Metformin 1000 mg Oral Tabletdrug

Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.

Glimepiride upto 4 mg Oral Tabletdrug

Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet